PURPOSE: To model locoregional recurrences of oropharyngeal squamous cell carcinomas (OSCC) treated with primary intensity modulated radiation therapy (IMRT) in order to find the origins from which recurrences grow and relate their location to original target volume borders. METHODS AND MATERIALS: This was a retrospective analysis of OSCC treated with primary IMRT between January 2002 and December 2009. Locoregional recurrence volumes were delineated on diagnostic scans and coregistered rigidly with treatment planning computed tomography scans. Each recurrence was analyzed with two methods. First, overlapping volumes of a recurrence and original target were measured ('volumetric approach') and assessed as 'in-field', 'marginal', or 'out-field'. Then, the center of mass (COM) of a recurrence volume was assumed as the origin from where a recurrence expanded, the COM location was compared with original target volume borders and assessed as 'in-field', 'marginal', or 'out-field'. RESULTS: One hundred thirty-one OSCC were assessed. For all patients alive at the end of follow-up, the mean follow-up time was 40 months (range, 12-83 months); 2 patients were lost to follow-up. The locoregional recurrence rate was 27%. Of all recurrences, 51% were local, 23% were regional, and 26% had both local and regional recurrences. Of all recurrences, 74% had imaging available for assessment. Regarding volumetric analysis of local recurrences, 15% were in-field gross tumor volume (GTV), and 65% were in-field clinical tumor volume (CTV). Using the COM approach, we found that 70% of local recurrences were in-field GTV and 90% were in-field CTV. Of the regional recurrences, 25% were volumetrically in-field GTV, and using the COM approach, we found 54% were in-field GTV. The COM of local out-field CTV recurrences were maximally 16 mm outside CTV borders, whereas for regional recurrences, this was 17 mm. CONCLUSIONS: The COM model is practical and specific for recurrence assessment. Most recurrences originated in the GTV. This suggests radioresistance in certain tumor parts.
PURPOSE: To model locoregional recurrences of oropharyngeal squamous cell carcinomas (OSCC) treated with primary intensity modulated radiation therapy (IMRT) in order to find the origins from which recurrences grow and relate their location to original target volume borders. METHODS AND MATERIALS: This was a retrospective analysis of OSCC treated with primary IMRT between January 2002 and December 2009. Locoregional recurrence volumes were delineated on diagnostic scans and coregistered rigidly with treatment planning computed tomography scans. Each recurrence was analyzed with two methods. First, overlapping volumes of a recurrence and original target were measured ('volumetric approach') and assessed as 'in-field', 'marginal', or 'out-field'. Then, the center of mass (COM) of a recurrence volume was assumed as the origin from where a recurrence expanded, the COM location was compared with original target volume borders and assessed as 'in-field', 'marginal', or 'out-field'. RESULTS: One hundred thirty-one OSCC were assessed. For all patients alive at the end of follow-up, the mean follow-up time was 40 months (range, 12-83 months); 2 patients were lost to follow-up. The locoregional recurrence rate was 27%. Of all recurrences, 51% were local, 23% were regional, and 26% had both local and regional recurrences. Of all recurrences, 74% had imaging available for assessment. Regarding volumetric analysis of local recurrences, 15% were in-field gross tumor volume (GTV), and 65% were in-field clinical tumor volume (CTV). Using the COM approach, we found that 70% of local recurrences were in-field GTV and 90% were in-field CTV. Of the regional recurrences, 25% were volumetrically in-field GTV, and using the COM approach, we found 54% were in-field GTV. The COM of local out-field CTV recurrences were maximally 16 mm outside CTV borders, whereas for regional recurrences, this was 17 mm. CONCLUSIONS: The COM model is practical and specific for recurrence assessment. Most recurrences originated in the GTV. This suggests radioresistance in certain tumor parts.
Authors: Abdallah S R Mohamed; Carlos E Cardenas; Adam S Garden; Musaddiq J Awan; Crosby D Rock; Sarah A Westergaard; G Brandon Gunn; Abdelaziz M Belal; Ahmed G El-Gowily; Stephen Y Lai; David I Rosenthal; Clifton D Fuller; Michalis Aristophanous Journal: Radiother Oncol Date: 2017-07-31 Impact factor: 6.280
Authors: M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani Journal: Eur Arch Otorhinolaryngol Date: 2016-12-09 Impact factor: 2.503
Authors: Anne K Due; Ivan R Vogelius; Marianne C Aznar; Søren M Bentzen; Anne K Berthelsen; Stine S Korreman; Annika Loft; Claus A Kristensen; Lena Specht Journal: Radiother Oncol Date: 2014-06-30 Impact factor: 6.280
Authors: Stuart E Samuels; Avraham Eisbruch; Jonathan J Beitler; June Corry; Carol R Bradford; Nabil F Saba; Michiel W M van den Brekel; Robert Smee; Primož Strojan; Carlos Suárez; William M Mendenhall; Robert P Takes; Juan P Rodrigo; Missak Haigentz; Alexander D Rapidis; Alessandra Rinaldo; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2015-10-13 Impact factor: 3.236
Authors: Abdallah S R Mohamed; David I Rosenthal; Musaddiq J Awan; Adam S Garden; Esengul Kocak-Uzel; Abdelaziz M Belal; Ahmed G El-Gowily; Jack Phan; Beth M Beadle; G Brandon Gunn; Clifton D Fuller Journal: Radiat Oncol Date: 2016-07-26 Impact factor: 3.481
Authors: Abdallah S R Mohamed; Andrew J Wong; Clifton D Fuller; Mona Kamal; Gary B Gunn; Jack Phan; William H Morrison; Beth M Beadle; Heath Skinner; Stephen Y Lai; Sean R Quinlan-Davidson; Abdelaziz M Belal; Ahmed G El-Gowily; Steven J Frank; David I Rosenthal; Adam S Garden Journal: Radiat Oncol Date: 2017-08-15 Impact factor: 3.481
Authors: David Bird; Andrew F Scarsbrook; Jonathan Sykes; Satiavani Ramasamy; Manil Subesinghe; Brendan Carey; Daniel J Wilson; Neil Roberts; Gary McDermott; Ebru Karakaya; Evrim Bayman; Mehmet Sen; Richard Speight; Robin J D Prestwich Journal: BMC Cancer Date: 2015-11-04 Impact factor: 4.430